Omeros Corporation Email Format
Biotechnology ResearchWashington, United States201-500 Employees
Omeros Corporation is a Seattle-based biotechnology company focused on discovering, developing, and commercializing therapeutics in both small-molecule and protein formats. Its programs target inflammation, coagulopathies, and disorders of the central nervous system, pursuing options for broad patient populations as well as orphan indications. Situated in the biopharmaceutical sector, the company operates with a mid-sized workforce based in Seattle. In 2026, Omeros announced a collaboration with Novo Nordisk to develop and commercialize zaltenibart for rare blood and kidney disorders.